CSHS WWW HOME | MS EXCHANGE LOG ON | PULSE ARCHIVES
Medical Staff Pulse is
a Publication of the Chief of Staff
Research Corner

Cedars-Sinai Opens Patient Trial of Virus that Attacks Brain Cancer Cells

A common, naturally occurring virus that attacks cancer cells but appears to
be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive brain tumors (gliomas). Researchers at Cedars-Sinai are among a few in the U.S. evaluating this experimental therapy.

Over the course of a lifetime, most adults will be exposed to the virus in its natural state. It commonly infects the lungs and intestines but -- unlike most viruses -- causes few if any symptoms and is usually eliminated by the body within two weeks. But while the reovirus (respiratory enteric orphan virus) may be harmless to normal cells, it can specifically kill certain cancer cells.

Vulnerable cancer cells have a defect in a signaling pathway (the Ras pathway) that controls key cell functions. The reovirus is able to infect and kill cancer cells that have an "activated" Ras pathway, but the virus does not normally come into contact with cancer cells. Researchers at Oncolytics Biotech Inc., of Calgary, Canada, developed a therapeutic drug, REOLYSIN®, from the reovirus and are conducting multi-center clinical trials for a variety of cancers.

Cedars-Sinai is participating only in the study on recurrent gliomas, the most common and deadly brain cancers.

Based on the fact that many types of cancer cells have an activated Ras pathway, the company estimates that up to two-thirds of all human cancers are susceptible to reovirus induced cell death.

"Although not every glioma cell line has an activated Ras pathway, Ras activation is very common in these malignant brain cancers. In lab tests and animal studies, the reovirus appears to target Ras-activated tumor cells and leave normal cells alone," said neurosurgeon John S. Yu, M.D., director of Surgical Neuro-oncology at Cedars-Sinai's Department of Neurosurgery. Dr. Yu is principal investigator of the clinical trial at Cedars-Sinai.

The glioma study is offered through the Cochran Brain Tumor Center at Cedars-Sinai. According to the protocol of this open-label Phase I and II trial, patients will receive a single treatment of REOLYSIN®, infused over 72 hours and directed into the tumor under sophisticated guidance. Expected length of hospital stay is about five days, and patients' progress will be followed for at least 12 weeks.